App-Quantinova.ai

Phase 1 study to characterize the pharmacokinetics and safety of tazemetostat in b-cell lymphomas or advanced solid tumors

Evren Kocabas Argon - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tazemetostat

FBXL12 modulates Fanconi anaemia-BRCA signaling under conditions of oncogene-induced replication stress

Andr Brunner - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry

Burcu F. Darst - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Identification of 22 novel loci associated with susceptibility to testicular germ cell tumors

John Pluta - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

Preclinical investigation of ATR inhibition alone and in combination with PARP inhibition in high risk neuroblastoma

Harriet E. Southgate - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Olaparib

Molecular profiling of the desmoplastic reaction within the colorectal tumor microenvironment using the nCounter® platform

Ines P. Nearchou - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Roles for the cancer stem cell marker Aldh1A1 in Merlin null nervous system tumors

Lily Hillson - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

merlin

Understanding immune recruitment and activation via virally delivered IL-12

Nicholas M. Durham - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

GM-CSF

Targeting MTHFD2 using first-in-class inhibitors kills haematological and solid cancer through thymineless-induced replication stress

Thomas Helleday - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

PERSPECTIVE, a randomized phase 3 study

Nathan Fowler - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Ibrutinib

Glutamine fuels the TCA cycle in VHL and FH mutant renal cell carcinoma

Akash K. Kaushik - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Glutamine

Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

James S. Scott - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

Fulvestrant

Population estimates of prostate cancer risk and prognosis for carriers of germline pathogenic variants in disease implicated genes, using 200,000 UK Biobank whole exomes

Niedzica Camacho - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Robust correlation of Galectin-9 expression with immunological tumor features and outcome in multiple tumor types establishes it as both a novel therapeutic target and a biomarker

Aleksandra Filipovic - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

galectin-9

BCAT1 as a druggable target in immuno-oncology

Adonia E. Papathanassiu - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Interferon Gamma

Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma

Marlana Orloff - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Uveal melanoma

IMCgp100

Cancer dependency signatures for line of sight genomic alterations in squamous cell lung cancer yield rational targets

Miika Ahdesmki - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Exposure versus efficacy/safety of acalabrutinib and its pharmacologically active metabolite, ACP-5862, for the treatment of chronic lymphocytic leukemia

Helena Edlund - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic Lymphocytic Leukemia

ACP-196

A recombinant Newcastle disease virus expressing IL-12 has potent pre-clinical immunomodulatory and anti tumor properties

James Harper - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon

Tebentafusp recognition of melanoma cells is restricted by HLA-A0201 presentation of a gp100 peptide

David Cole - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

GP100

Filters

45280 Abstracts